KDR and acute lymphoblastic leukemia: However, in our small-molecule inhibitor screen with T-ALL cells, we have not seen consistent activity of FLT-3/c-KIT inhibitor (sunitinib), FGFR1/3 inhibitor (ponatinib), or VEGFR inhibitor (sorafenib, AMG 706) [45], suggesting further investigation needed to identify the specific targets for dovitinib in T-ALL.